Objective:
To evaluate the safety and efficacy of ATSN-201 for the treatment of X-linked retinoschisis (XLRS) in a phase 1/2 clinical trial.
Key Findings:
- ATSN-201 was well tolerated with no serious adverse events related to treatment.
- Adverse events were primarily related to the surgical procedure and were of Grade 1-2 severity.
- No dose-limiting toxicities were observed, and no subjects discontinued from the study.
Interpretation:
The preliminary results indicate that ATSN-201 is a promising candidate for treating XLRS, demonstrating good safety and tolerability.
Limitations:
- The study is still ongoing, and results are preliminary.
- Part A involved a small sample size of only 9 adult patients.
Conclusion:
Enrollment is underway for Part B of the study, which will further assess safety and efficacy in a larger cohort, including pediatric patients.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.